Novel fused pyrimidine and isoquinoline derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2016105532A1, WO2016105534A1 and WO2016105564A1

References

• Zhan P, Pannecouque C, De CE, et al. Anti-HIV drug discovery and development: current innovations and future trends. J Med Chem. 2016;59:2849-2878. ​ ​
   Web of Science ®Google Scholar
• Esté JA, Cihlar T. Current status and challenges of antiretroviral research and therapy. Antiviral Res. 2010;85:25–33.
   PubMed Web of Science ®Google Scholar
• Li D, Zhan P, De CE, et al. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms. J Med Chem. 2012;55:3595–3613.
   PubMed Web of Science ®Google Scholar
• Zhan P, Chen X, Li D, et al. HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design. Med Res Rev. 2013;33(Suppl 1):E1–E72.
   PubMed Web of Science ®Google Scholar
• Béthune M-P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009). Antiviral Res. 2010;85:75–90.
   PubMed Web of Science ®Google Scholar
• Johnson VA, Calvez V, Günthard HF, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2011;19:156–164.
   PubMedGoogle Scholar
• Chen X, Zhan P, Li D, et al. Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. Curr Med Chem. 2011;18:359–376.
   PubMed Web of Science ®Google Scholar
• Corte BLD. From 4,5,6,7-tetrahydro-5-methylimidazo [4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Med Chem. 2005;48:1689–1696.
   PubMed Web of Science ®Google Scholar
• Lansdon EB, Brendza KM, Hung M, et al. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J Med Chem. 2010;53:4295–4299.
   PubMed Web of Science ®Google Scholar
• Das K, Clark AD Jr., Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem. 2004;47:2550–2560.
   PubMed Web of Science ®Google Scholar
• Huang B, Kang D, Yang J, et al. Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1. Expert Opin Ther Pat. 2016;26:281–289.
   PubMed Web of Science ®Google Scholar
• Jansa PK, Miroslav, Mackman RL, Preparation of purines, azapurines, and deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV infection. WO 2006122003 A2 (2016).
   Google Scholar
• Jansa P, Mackman RL, Hu Y, et al. Preparation of isoquinoline compounds as HIV Reverse transcriptase inhibitors useful in treatment and prevention of HIV infection. WO 2016105534 A1. 2016.
   Google Scholar
• Jansa PS, Lansdon T, Hu E, et al. Preparation of quinazoline derivatives for the treatment of HIV infection. WO 2016105564 A1. 2016.
   Google Scholar
• Gintant G, Sager PT, Stockbridge N. Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov. 2016;15:457–471.
   PubMed Web of Science ®Google Scholar
• Danker T, Möller C. Early identification of hERG liability in drug discovery programs by automated patch clamp. Front Pharmacol. 2014;5:203.
   PubMed Web of Science ®Google Scholar
• Fang Z, Song Y, Zhan P, et al. Conformational restriction: an effective tactic in ‘follow-on’-based drug discovery. Future Med Chem. 2014;6:885–901.
   PubMed Web of Science ®Google Scholar
• Johnson BC, Pauly GT, Rai G, et al. A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants. Retrovirology. 2012;9:1–11.
   PubMed Web of Science ®Google Scholar
• Rimsky L, Vingerhoets J, Van EV, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. JAIDS J Acquir Immune Defic Syndr. 2012;59:39–46.
   PubMed Web of Science ®Google Scholar
• Girardet JLK, Yung-Hyo, Shaw S, et al. Preparation of purines, azapurines, and deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV infection. WO 2006122003 A2. 2006.
   Google Scholar
• Girardet J-LH, Zhi, Shaw S, et al. Cyanophenylamino-substituted thienopyrimidine compounds as non-nucleoside reverse transcriptase inhibitors, their preparation, pharmaceutical compositions, and use as anti-HIV treatment. WO 2008058285 A2. 2008.
   Google Scholar
• Kang D, Fang Z, Li Z, et al. Design, synthesis, and evaluation of thiophene[3,2-d]pyrimidine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors with significantly improved drug resistance profiles. J Med Chem. 2016;59:7991–8007.
   PubMed Web of Science ®Google Scholar
• Tian Y, Du D, Rai D, et al. Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives. Bioorg Med Chem. 2014;22:2052–2059.
   PubMed Web of Science ®Google Scholar
• Wang L, Tian Y, Chen W, et al. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach. Eur J Med Chem. 2014;85:293–303.
   PubMed Web of Science ®Google Scholar
• Huang B, Li C, Chen W, et al. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. Eur J Med Chem. 2015;92:754–765.
   PubMed Web of Science ®Google Scholar
• Bollini M, Domaoal RA, Thakur VV, et al. Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. J Med Chem. 2011;54:8582–8591.
   PubMed Web of Science ®Google Scholar
• Fleming FF, Wang Q. Unsaturated nitriles: conjugate additions of carbon nucleophiles to a recalcitrant class of acceptors. Chem Rev. 2003;103:2035–2077.
   PubMed Web of Science ®Google Scholar
• Lee W-G, Gallardo-Macias R, Frey KM, et al. Picomolar inhibitors of HIV reverse transcriptase featuring bicyclic replacement of a cyanovinylphenyl group. J Am Chem Soc. 2013;135:16705–16713.
   PubMed Web of Science ®Google Scholar
• Lee W-G, Frey KM, Gallardo-Macias R, et al. Picomolar inhibitors of HIV-1 reverse transcriptase: design and crystallography of naphthyl phenyl ethers. ACS Med Chem Lett. 2014;5:1259–1262.
   PubMed Web of Science ®Google Scholar
• Lee W-G, Frey KM, Gallardo-Macias R, et al. Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett. 2015;25:4824–4827.
   PubMed Web of Science ®Google Scholar
• Frey KM, Puleo DE, Spasov KA, et al. Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants. J Med Chem. 2015;58:2737–2745.
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X, Li Z, et al. Design strategies of novel NNRTIs to overcome drug resistance. Curr Med Chem. 2009;16:3903–3917.
   PubMed Web of Science ®Google Scholar
• Song Y, Zhan P, Li X, et al. Multivalent agents: a novel concept and preliminary practice in anti-HIV drug discovery. Curr Med Chem. 2013;20(818):815–832.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang L, Tian Y, et al. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011–2014). Expert Opin Ther Pat. 2014;24:1199–1227.
   PubMed Web of Science ®Google Scholar
• Wang S, Sun H, Liu H, et al. ADMET evaluation in drug discovery. 16. Predicting hERG blockers by combining multiple pharmacophores and machine learning approaches. Mol Pharm. 2016;13:2855–2866. ​
   Web of Science ®Google Scholar
• Gleeson MP, Hersey A, Montanari D, et al. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov. 2011;10:197–208.
   PubMed Web of Science ®Google Scholar